Wuxi Bio(02269.HK) announced that its four bio-pharmaceutical bulk liquid and bio-pharmaceutical preparation factories in Wuxi and Suzhou testing center recently obtained GMP certification from the European Medicines Agency (EMA) once again, demonstrating the company's adherence to international industry quality standards. Currently, Wuxi Bio's global production network includes 15 bio-pharmaceutical bulk liquid and preparation production factories certified by pharmaceutical regulatory institutions.

Wuxi Bio's bio-pharmaceutical bulk liquid plants 1, 2, and 5 (MFG1, MFG2, MFG5) and bio-pharmaceutical preparation plant 1 (DP1) in Wuxi have successfully passed the comprehensive inspection conducted by the EU EMA for 8 drugs produced by the company for customers in commercialization and new drug application (NDA) stages. In addition, Suzhou testing center has also obtained GMP certification from EMA for 10 innovative drugs, including the aforementioned 8 innovative drugs.